News Column

Researchers from Fudan University Discuss Findings in Solid Cancer (Phase I and pharmacokinetic study of polymeric micelle-formulated paclitaxel in...

June 30, 2014



Researchers from Fudan University Discuss Findings in Solid Cancer (Phase I and pharmacokinetic study of polymeric micelle-formulated paclitaxel in adult Chinese patients with advanced solid tumors)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Oncology. According to news originating from Shanghai, People's Republic of China, by NewsRx correspondents, research stated, "Polymeric micelle-formulated paclitaxel (PM paclitaxel) is a nanoscale drug delivery compound. This study investigated the maximum tolerated dose (MTD), dose-limiting toxicities, and pharmacokinetic (PK) profile of PM paclitaxel in Chinese patients with treatment-refractory advanced or relapsed solid tumors."

Our news journalists obtained a quote from the research from Fudan University, "Dose escalation of PM paclitaxel followed the standard '3 + 3' rule, starting at 175 mg/m(2). PM paclitaxel was administered over 3 h every 3 weeks. Patients were treated until disease progression, intolerance, death, or consent withdrawal. Blood samples were collected for PK testing. All 23 patients were evaluable for toxicity. Neutropenia, neuropathy, and myalgia were the most common toxicities; acute hypersensitivity reaction was not observed. One of six patients at dose level 4 (350 mg/m(2)) and two of six patients at dose level 5 (390 mg/m(2)) developed grade 4 neutropenia. The MTD was 350 mg/m(2). No patients discontinued treatment because of neuropathy. Partial response was seen in five of 20 patients (25 %) who had response assessment, three of whom had prior exposure to taxanes (two were heavily pretreated). Ten patients (50 %) had stable disease at cycle 2 and only five patients (25 %) had disease progression. The area under the curve and the maximum concentration of paclitaxel increased with escalating doses, suggesting that PM paclitaxel has linear PKs. The main dose-limiting toxicity for PM paclitaxel was neutropenia, and the recommended dose for phase II study is 300 mg/m(2)."

According to the news editors, the research concluded: "PM paclitaxel is superior to conventional paclitaxel for its simplified premedication regimen and delivery of a higher paclitaxel dose without increased neuropathy."

For more information on this research see: Phase I and pharmacokinetic study of polymeric micelle-formulated paclitaxel in adult Chinese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2014;73(6):1173-1179. Cancer Chemotherapy and Pharmacology can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA. (Springer - www.springer.com; Cancer Chemotherapy and Pharmacology - www.springerlink.com/content/0344-5704/)

The news correspondents report that additional information may be obtained from F.F. Lv, Fudan University, Shanghai Med College, Dept. of Oncol, Shanghai 200433, People's Republic of China. Additional authors for this research include J.N. Cao, J. Zhang, J. Qian, W. Peng, S. Sun, W.H. Li, W. Zhang, W.J. Guo and J. Li (see also Oncology).

Keywords for this news article include: Asia, Antineoplastics, Pharmaceuticals, Drugs, Taxoids, Therapy, Shanghai, Oncology, Terpenes, Leukopenia, Paclitaxel, Neutropenia, Hydrocarbons, Solid Cancers, Cycloparaffins, Agranulocytosis, Pharmacokinetics, Organic Chemicals, Mitotic Inhibitors, Leukocyte Disorders, Hematologic Diseases, People's Republic of China

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Clinical Trials Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters